PL1689410T3 - Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu - Google Patents

Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu

Info

Publication number
PL1689410T3
PL1689410T3 PL04803177T PL04803177T PL1689410T3 PL 1689410 T3 PL1689410 T3 PL 1689410T3 PL 04803177 T PL04803177 T PL 04803177T PL 04803177 T PL04803177 T PL 04803177T PL 1689410 T3 PL1689410 T3 PL 1689410T3
Authority
PL
Poland
Prior art keywords
17beta
estra
trien
diol
vinyl
Prior art date
Application number
PL04803177T
Other languages
English (en)
Inventor
Christa Hegele-Hartung
Karl-Heinrich Fritzemeier
Olaf Peters
Theo Pelzer
Ludwig Neyses
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PL1689410T3 publication Critical patent/PL1689410T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL04803177T 2003-11-26 2004-11-16 Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu PL1689410T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26
EP04803177A EP1689410B1 (en) 2003-11-26 2004-11-16 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
PCT/EP2004/013121 WO2005051401A2 (en) 2003-11-26 2004-11-16 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol

Publications (1)

Publication Number Publication Date
PL1689410T3 true PL1689410T3 (pl) 2008-10-31

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04803177T PL1689410T3 (pl) 2003-11-26 2004-11-16 Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu

Country Status (16)

Country Link
US (1) US20050148560A1 (pl)
EP (1) EP1689410B1 (pl)
JP (1) JP2007512279A (pl)
AR (1) AR046672A1 (pl)
AT (1) ATE395919T1 (pl)
DE (1) DE602004014020D1 (pl)
DK (1) DK1689410T3 (pl)
ES (1) ES2307064T3 (pl)
GT (1) GT200400241A (pl)
PA (1) PA8618401A1 (pl)
PE (1) PE20050665A1 (pl)
PL (1) PL1689410T3 (pl)
PT (1) PT1689410E (pl)
TW (1) TW200530263A (pl)
UY (1) UY28630A1 (pl)
WO (1) WO2005051401A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CA2676066C (en) 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2143432A1 (en) * 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
HUP0300335A2 (hu) * 2000-04-12 2003-07-28 Schering Ag. 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
ATE395919T1 (de) 2008-06-15
PE20050665A1 (es) 2005-11-02
AR046672A1 (es) 2005-12-14
PT1689410E (pt) 2008-08-18
WO2005051401A3 (en) 2005-09-01
US20050148560A1 (en) 2005-07-07
GT200400241A (es) 2005-10-31
EP1689410A2 (en) 2006-08-16
DE602004014020D1 (de) 2008-07-03
TW200530263A (en) 2005-09-16
ES2307064T3 (es) 2008-11-16
DK1689410T3 (da) 2008-09-08
JP2007512279A (ja) 2007-05-17
WO2005051401A2 (en) 2005-06-09
UY28630A1 (es) 2005-06-30
EP1689410B1 (en) 2008-05-21
PA8618401A1 (es) 2005-08-04

Similar Documents

Publication Publication Date Title
IL173439A0 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PL1656346T3 (pl) 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1578719A4 (en) P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
EP1545558A4 (en) 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
IL158115A0 (en) Sapogenin derivatives, their synthesis and use, and methods based upon their use
PL1689410T3 (pl) Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1617810A4 (en) PROCESS FOR THE PREPARATION AND USE OF 1ALPHA, 24 (S) -DIHYDROXYVITAMINE D2
WO2005063757A3 (en) Novel crystalline forms of temozolomide
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
PL376756A1 (pl) Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych
ZA200405173B (en) 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
PL375309A1 (pl) Pochodne acyloksypirolidyny, ich wytwarzanie i ich zastosowanie lecznicze
AU2002365941A8 (en) Methods of diagnosis, monitoring and treatment of fertility
GB0300078D0 (en) Composition for the treatment of HIV and AIDS
AU2002357561A8 (en) Oxazolidine derivative, methods of preparation and uses